AIM Biotech
Singapore, Singapore· Est.
AIM Biotech delivers scalable human‑on‑a‑chip platforms to replace animal models in drug discovery.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AIM Biotech delivers scalable human‑on‑a‑chip platforms to replace animal models in drug discovery.
OncologyImmuno-oncologyVascular BiologyNeurobiology
Technology Platform
Humanized 3‑D microfluidic organ‑on‑a‑chip platforms (idenTx and organiX) that integrate standardized cell sources with perfusable vasculature and co‑culture capabilities for predictive drug testing.
Opportunities
Growing regulatory demand for non‑animal models and pharma’s need for predictive human‑relevant data create strong market pull for AIM’s scalable MPS platforms.
Risk Factors
Adoption depends on validation against clinical outcomes and competition from established organ‑on‑a‑chip players; technical scaling and regulatory acceptance remain challenges.
Competitive Landscape
Key competitors include Emulate, Mimetas, and TissUse; AIM differentiates through its plug‑and‑play chip design, gas‑permeable laminates, and integrated contract‑research services.